To date, 2024 has not yet seen the type of mega-merger (Pfizer/Seagen) or level of agency enforcement (Sanofi/Maze or Amgen/Horizon) as 2023. But two notable investigations — one still active — show the Federal Trade...more
9/10/2024
/ AbbVie ,
Abuse of Dominance ,
Acquisitions ,
Amgen ,
Antitrust Investigations ,
Antitrust Provisions ,
Eli Lilly ,
EU ,
European Commission ,
Federal Trade Commission (FTC) ,
Food and Drug Administration (FDA) ,
Horizontal Mergers ,
Life Sciences ,
Mergers ,
Orange Book ,
Patents ,
Pfizer ,
Pharmaceutical Industry ,
Pharmacy Benefit Manager (PBM) ,
Popular ,
Sanofi ,
Supply Chain ,
Vertical Mergers
Antitrust actions significantly impacted the technology sector in 2023 and are poised to have substantial repercussions in the future, affecting both major tech companies and emerging enterprises. In addition to a focus on...more
The FTC’s Amgen/Horizon Lawsuit Ends With a Whimper -
We covered the FTC’s investigation into (and litigation challenging) Amgen’s $28.3 billion acquisition of rare disease specialist Horizon Therapeutics in our Q1 and...more
10/24/2023
/ Acquisitions ,
Antitrust Provisions ,
Clinical Trials ,
Draft Guidance ,
Enforcement ,
Hart-Scott-Rodino Act ,
Life Sciences ,
Mergers ,
Pfizer ,
Pharmaceutical Industry ,
Popular ,
Settlement
The start of 2023 has been a busy one, with global antitrust agencies advancing investigations and challenging a number of technology acquisitions. Future antitrust enforcement could also be shaped by new digital market...more
6/15/2023
/ Acquisitions ,
Adobe ,
Antitrust Division ,
Broadcom ,
Competition ,
Competition Authorities ,
Digital Marketplace ,
Divestiture ,
Enforcement Priorities ,
EU ,
Facebook ,
Federal Trade Commission (FTC) ,
Microsoft ,
Popular ,
Proposed Legislation ,
Remedies ,
UK ,
UK Competition and Markets Authority (CMA)
Our prior updates covered how FTC enforcement activity largely proceeded “as usual” during 2022 in the life sciences industry, with large pharmaceutical players buying or licensing promising, but still risky, assets from...more
5/25/2023
/ Acquisitions ,
Amgen ,
Corporate Practice of Medicine ,
Enforcement Priorities ,
Federal Trade Commission (FTC) ,
Life Sciences ,
Mergers ,
Pfizer ,
Pharmaceutical Industry ,
Pharmacy Benefit Manager (PBM) ,
Popular
2022 saw a major uptick in antitrust scrutiny and enforcement, primarily related to vertical transactions by large technology companies. Meta/Within, Microsoft/Activision, and Broadcom/VMware (among others) faced resistance...more
2/22/2023
/ Acquisitions ,
Anti-Competitive ,
Antitrust Provisions ,
Broadcom ,
Competition ,
Federal Trade Commission (FTC) ,
Horizontal Mergers ,
Mergers ,
Microsoft ,
Popular ,
Technology ,
Technology Sector ,
UK Competition and Markets Authority (CMA)
M&A activity in the life sciences space proceeded largely as usual in 2022, with most transactions receiving expected levels of agency scrutiny and closing in the normal course despite aggressive rhetoric from new leadership...more
2/22/2023
/ Acquisitions ,
Amgen ,
Antitrust Provisions ,
Biotechnology ,
Bristol-Myers Squibb ,
Department of Justice (DOJ) ,
Federal Trade Commission (FTC) ,
GlaxoSmithKline ,
Life Sciences ,
Mergers ,
Novo Nordisk ,
Pfizer ,
Pharmaceutical Industry ,
Popular ,
Risk Management
Two major technology companies, Meta and Microsoft, continue to defend their acquisitions against challenges from antitrust regulators. The FTC dropped one of the two claims underlying its challenge of Meta’s acquisition of...more
11/10/2022
/ Acquisitions ,
Antitrust Investigations ,
Antitrust Provisions ,
Competition ,
EU ,
European Commission ,
Facebook ,
Federal Trade Commission (FTC) ,
Mergers ,
Microsoft ,
Mobile Apps ,
Popular ,
UK ,
UK Competition and Markets Authority (CMA)
The third quarter in the life sciences space showed that business is generally proceeding as usual, with large pharma players successfully acquiring or licensing in clinical stage assets without running into antitrust delays....more
11/10/2022
/ Acquisitions ,
Antitrust Division ,
Antitrust Provisions ,
Bristol-Myers Squibb ,
Competition ,
Department of Justice (DOJ) ,
Federal Trade Commission (FTC) ,
GlaxoSmithKline ,
Health Technology ,
Life Sciences ,
Mergers ,
Metadata ,
Mobile Apps ,
Pfizer ,
Pharmaceutical Industry ,
Popular ,
Virtual Reality
In July 2022, the FTC brought an enforcement action to enjoin Meta’s acquisition of virtual reality app maker Within. The FTC’s approach in that complaint could have implications for Microsoft’s proposed acquisition of...more
8/16/2022
/ Acquisitions ,
Amazon ,
Antitrust Investigations ,
Antitrust Provisions ,
App Developers ,
Big Tech ,
Broadcom ,
Facebook ,
Federal Trade Commission (FTC) ,
Google ,
Horizontal Mergers ,
Microsoft ,
Mobile Apps ,
Popular ,
Vertical Mergers ,
Video Games ,
Virtual Reality
Although the second quarter did not feature any life sciences enforcement action by the FTC, there was plenty of news in and around the space. The FTC held a detailed “virtual workshop” as part of its pharmaceutical...more